Key Takeaways
- •Peptide purity is the percentage of the target sequence relative to total peptide-related material, normally measured as peak area by reversed-phase HPLC.
- •It is a different quantity from peptide content, which is how much actual peptide is in the vial once counterions and water are excluded. A sample can be 99% pure and still be mostly salt.
- •A purity figure is uncheckable without its method and its detection wavelength: 214 to 220 nm reads the peptide bond and sees everything, 280 nm reads aromatic side chains and sees only peptides containing one.
- •HPLC cannot establish identity. It establishes that one species dominates, and mass spectrometry is what confirms the dominant species is the right molecule.
- •Common synthesis impurities are peptides too: truncated and deletion sequences, aspartimide and related rearrangements, oxidation at methionine, cysteine and tryptophan, and racemised residues. They can bind the same receptor as the target.
- •No regulatory standard governs research-grade purity. Suppliers set their own specifications, which is why transparent reporting of method, wavelength and impurity profile matters more than the number.
Summary
Peptide purity is the share of the material that is the sequence you ordered, as a percentage of total peptide content. In practice it is measured by reversed-phase HPLC, with mass spectrometry run alongside it to confirm that the main peak is the right molecule rather than merely a single one.
What the rest of the material is matters. Solid-phase synthesis leaves behind truncated and deletion sequences, rearrangement products, oxidation products and residual solvent, and those are peptides too: they can bind the same receptor, which is how an impurity ends up inside a dose-response curve rather than beside it.
There is no regulatory standard for research-grade purity. Every supplier sets its own specification, which is why a number on its own means little. A purity figure is checkable only when it names the method and the detection wavelength, because 220 nm reads the peptide bond and 280 nm reads aromatic side chains, and a peptide with no aromatic residue reads very differently at the two.
What Is Peptide Purity?
Peptide purity refers to the proportion of the desired sequence in a synthesised sample, expressed as a percentage of total peptide-related material. For research peptides it is most commonly assessed by reversed-phase HPLC, where the area under the target peak is compared with the total area of all peptide-related peaks.
Three quantities are routinely confused and they answer different questions:
- Chromatographic purity is the area percent of the main peak. It says one species dominates the peptide-related material.
- Peptide content is how much of the vial is peptide at all, once counterions and residual water are excluded. It is reported in milligrams and it is what determines the molar concentration you actually prepare.
- Identity is whether the dominant species is the sequence on the label. Neither of the first two establishes it.
HPLC alone cannot distinguish isobaric impurities, so the target sequence is confirmed by mass spectrometry against the theoretical monoisotopic mass. Common impurities include:
- Truncated sequences from incomplete coupling during solid-phase synthesis.
- Deletion peptides missing one or more residues after a failed coupling or deprotection.
- Aspartimide and related rearrangements, a well-characterised Fmoc-SPPS side reaction at aspartate-containing sequences that produces species very close in mass to the target (PMID 12587881, PMID 12952393).
- Oxidation products, particularly at methionine, cysteine or tryptophan.
- Racemisation products, D-amino acid isomers that can alter bioactivity and are invisible to a mass measurement.
- Residual solvents and counterions from cleavage and purification, typically acetonitrile and trifluoroacetic acid.
What Each Method Measures, and What It Cannot
The useful question is not which method is best but which question each one answers.
Reversed-phase HPLC separates peptides by hydrophobicity. A C18 stationary phase retains hydrophobic species while a gradient of organic solvent, usually acetonitrile with 0.1% TFA, elutes them, so impurities of differing hydrophobicity leave at different retention times and can be quantified by peak area. What it cannot do is tell you what any peak is. A single sharp peak says one substance dominates; it does not say which substance (PMID 18604941).
Mass spectrometry identifies species by mass-to-charge ratio. Electrospray or matrix-assisted laser desorption ionisation generates ions analysed by time-of-flight or quadrupole detectors, and the observed mass is compared with the theoretical monoisotopic mass. What it cannot do is distinguish species of identical mass, which includes every rearrangement of the same residues, every leucine for isoleucine substitution, and every D-for-L substitution.
Capillary electrophoresis separates by electrophoretic mobility under an electric field, so it is sensitive to charge and size and can resolve impurities that co-elute on HPLC. It is complementary rather than confirmatory.
Amino acid analysis hydrolyses the peptide and quantifies the residues released, which verifies composition and gives a peptide content figure independent of chromatographic purity. It destroys the sample and says nothing about sequence order.
No single method characterises a peptide. Purity by HPLC, identity by MS and composition by AAA answer three separate questions, and a certificate reporting one of the three has answered one of them.
Why Impurities Change Results
Impurities in a research peptide are not inert ballast, and this is the part of the subject that matters at the bench rather than on the certificate.
A truncated or deletion sequence retains part of the target's binding surface, so it can act as a partial agonist or a competitive antagonist at the same receptor. The consequence is that it sits inside the dose-response relationship rather than diluting it: the concentration axis is wrong by an unknown amount, and in a selectivity comparison the error is not even consistent between receptors.
Oxidation products change behaviour rather than merely reducing yield. Methionine sulfoxide formation alters polarity and can alter binding, and it continues during handling and storage rather than being fixed at synthesis.
Residual trifluoroacetic acid, the usual counterion left by HPLC purification, is a separate problem from purity as such: it is cytotoxic at sufficient concentration and shifts pH and ion balance in cell culture. Removing it by lyophilisation from a different acid or by ion exchange is routine where assays are sensitive.
Racemised residues are the quietest of these, because the mass does not change. A D-residue substitution passes a mass check unaltered and can abolish binding.
The magnitude of all of this is poorly quantified in the open literature, and that is an honest statement of the evidence rather than a gap in this article. Most published peptide studies do not report the purity or impurity profile of the material used, so the relationship between purity and experimental outcome is largely inferred from analytical chemistry rather than measured against biological endpoints.
What the Detection Wavelength Does to the Number
A chromatographic purity figure is only meaningful alongside the wavelength it was measured at.
UV detection at 214 to 220 nm reads the peptide bond, which every peptide has, so it sees essentially all peptide-related material in the sample. Detection at 280 nm reads aromatic side chains, tryptophan, tyrosine and phenylalanine, so it only sees peptides containing at least one of them.
The consequence is practical. A peptide with no aromatic residue can return a strong, clean figure at 220 nm and almost nothing at 280 nm, and two certificates quoting different wavelengths are not comparable. When a purity claim carries no wavelength, it is not a number that can be checked.
How Strong Is the Evidence Here?
| Evidence Area | Strength | Notes |
|---|---|---|
| HPLC method validation for peptide purity | Strong | Established in pharmacopeial monographs and the analytical chemistry literature |
| Characterisation of common synthesis impurities | Strong for Fmoc-SPPS | Aspartimide formation, truncation and oxidation pathways are well described |
| Correlation between purity and bioactivity in cell assays | Low | Mechanistically expected and rarely measured systematically |
| Impact of purity on in vivo outcomes | Very low | No controlled studies identified |
| Standardisation of purity reporting across suppliers | Very low | No consensus; thresholds, methods and wavelengths all vary |
Two things are worth separating in that table. The analytical claims are strong: how chromatography and mass spectrometry work, and which impurities Fmoc synthesis produces, are settled questions with a large literature. The biological claims are weak, not because impurities plausibly do nothing, but because almost nobody has run the controlled experiment.
Limitations of This Evidence Base
- Reporting is not standardised. Suppliers and researchers frequently omit the threshold, the method, the wavelength and the impurity identification approach, which makes cross-study and cross-supplier comparison unreliable.
- "Greater than" claims conflate two metrics. A bare ">99%" may refer to chromatographic purity by HPLC or to peptide content by AAA. These are different numbers and the gap between them can be large.
- The biological consequences are mechanistically reasoned rather than measured. Specific published figures for how much a given impurity level shifts a given assay are scarce, and this article deliberately quotes none rather than repeat an unverifiable one.
- No pharmacopeial standard covers research-grade material. USP and Ph. Eur. publish monographs for approved peptide drugs such as insulin and calcitonin. Those monographs do not apply to research peptides, and no equivalent standard exists for them.
Where the Methods Are Going
- Ultra-high-performance liquid chromatography gives shorter run times and higher resolution than conventional HPLC, which improves detection of minor impurities.
- Two-dimensional liquid chromatography addresses mixtures where impurities co-elute in a single dimension.
- High-resolution mass spectrometry narrows the mass tolerance enough to separate species that a one-decimal-place figure treats as identical, which is where the lysine against glutamine problem is resolved.
- Reference standards for common impurities remain the principal gap. Quantifying an impurity properly requires a standard for it, and for most research peptides none is available to buy.
Frequently Asked Questions
What is the difference between peptide purity and peptide content?
Purity is the percentage of the target sequence relative to all peptide-related peaks in an HPLC chromatogram. Content is the actual weight of peptide in the sample once counterions such as TFA or acetate and residual water are excluded. A sample can be 99% pure by HPLC and have substantially lower peptide content, which is why the two figures must be read together.
Which analytical method is most reliable for purity assessment?
Reversed-phase HPLC with UV detection at 214 nm, which reads the peptide bond, is the most widely used and accepted method for the purity question specifically. It establishes homogeneity and not identity, so it needs mass spectrometry beside it for identity and amino acid analysis for composition. No single method is sufficient.
Why do purity claims vary between suppliers?
Because there is no universal standard to vary from. Some report area percent of the main peak on HPLC, others report peptide content by AAA, and the detection wavelength is often unstated. Ask for the chromatogram, the mass spectrum and the wavelength. The Quality & Testing page sets out the distinction between a specification and a measurement.
Can impurities affect my cell-based assay results?
Yes, and the mechanism is specific rather than general. Truncated sequences retain part of the binding surface and can act as competitive antagonists at the target receptor, so they distort the dose-response relationship rather than simply weakening it. Oxidation products can alter binding, and residual TFA affects pH and ion balance independently of the peptide. How large the effect is depends on the impurity and the assay, and it is rarely quantified in published work.
Are there any regulations governing research peptide purity?
No. Research peptides are not covered by FDA or EMA drug regulation, and purity specifications are set by the supplier. USP and Ph. Eur. monographs exist for approved peptide drugs but do not apply to research-grade material.
Does a single sharp HPLC peak mean the peptide is correct?
No. It means one species dominates the peptide-related material. It cannot say which species, and any rearrangement of the same residues, any leucine for isoleucine swap and any D-for-L substitution produces the same mass as well as potentially the same retention time. Identity is a separate measurement.
Further reading
- How to Read a Certificate of Analysis, the full walk-through of a peptide certificate, section by section.
- Peptide Identity Testing: What Actually Proves a Sequence, why a matching mass does not establish identity, worked through on a real sequence.
- Peptide Purity Testing: Why 99% Differs on a Tripeptide and a 44-mer, why the same percentage is not the same claim at different chain lengths.
- Quality & Testing, the release specification, and the distinction between a specification and a measurement.
References
- Fields, G. B., & Noble, R. L. (1990). "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids." International Journal of Peptide and Protein Research, 35(3), 161-214. PMID 2191922.
- Mergler, M., Dick, F., Sax, B., Weiler, P., & Vorherr, T. (2003). "The aspartimide problem in Fmoc-based SPPS. Part I." Journal of Peptide Science, 9(1), 36-46. PMID 12587881.
- Mergler, M., Dick, F., Sax, B., Stähelin, C., & Vorherr, T. (2003). "The aspartimide problem in Fmoc-based SPPS. Part II." Journal of Peptide Science, 9(8), 518-526. PMID 12952393.
- Mant, C. T., Chen, Y., Yan, Z., Popa, T. V., Kovacs, J. M., Mills, J. B., Tripet, B. P., & Hodges, R. S. (2007). "HPLC analysis and purification of peptides." Methods in Molecular Biology, 386, 3-55. PMID 18604941.
Bibliography audited 25 October 2026. Three references previously listed here could not be resolved to any record in PubMed and the quantitative claims resting on them have been removed rather than re-sourced: a 2000 paper attributed to Verlander on truncated impurities in a VIP analogue, a 2003 paper attributed to Mergler on methionine oxidation, and a 2018 American Peptide Society purity-reporting guideline. The Mergler entries above are that author's real 2003 work, on aspartimide formation, which is a genuine impurity pathway in the same synthesis chemistry.
Research-Only Disclaimer
This article is for informational and educational purposes only and is intended for qualified researchers and laboratory professionals. The compounds discussed are sold for laboratory research purposes only and are not approved for human consumption, clinical use, or therapeutic application. Volta Peptides does not supply any research peptide for administration to people or animals. Always consult relevant safety data sheets and institutional guidelines before handling. For full terms, see the Research Disclaimer.
Reviewed by the Volta Peptides Research Team
Consolidated 18 October 2026: merged from three shorter purity, HPLC and purification articles.
